![Akshay Vaishnaw](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Akshay Vaishnaw
Directeur/Membre du Conseil chez SCHOLAR ROCK HOLDING CORPORATION
Fortune : 6 M $ au 30/06/2024
Profil
Le Dr Akshay K. Vaishnaw est directeur indépendant de Scholar Rock Holding Corp. et d'Editas Medicine, Inc. et président de la recherche et du développement d'Alnylam Pharmaceuticals, Inc. et membre du Royal College of Physicians. Il siège au conseil d'administration de Scholar Rock Holding Corp, Scholar Rock, Inc. et Editas Medicine, Inc. Le Dr Vaishnaw était auparavant employé par Biogen Idec, Inc. en tant que directeur principal de la médecine translationnelle. Il a également siégé au conseil d'administration de Visterra, Inc. Il a obtenu son diplôme de premier cycle à l'université de Cardiff, un doctorat à la faculté de médecine de l'université de Cardiff et un doctorat à l'université de Londres.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
31/01/2024 | 23 289 ( 0,02% ) | 6 M $ | 30/06/2024 | |
27/06/2024 | 22 955 ( 0,03% ) | 191 215 $ | 30/06/2024 | |
EDITAS MEDICINE, INC.
-.--% | 30/05/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Akshay Vaishnaw
Sociétés | Poste | Début |
---|---|---|
ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 02/10/2023 |
SCHOLAR ROCK HOLDING CORPORATION | Directeur/Membre du Conseil | 21/05/2019 |
The Royal College of Physicians | Corporate Officer/Principal | 07/07/2009 |
Scholar Rock, Inc.
![]() Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | 01/05/2019 |
Hemab Therapeutics ApS
![]() Hemab Therapeutics ApS BiotechnologyHealth Technology Hemab Therapeutics ApS is a clinical-stage biotech company based in Copenhagen, Denmark and MA. The Danish company is focused on developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company's strategic guidance, Hemab 1-2-5tm, targets the development of 5 independent assets by 2025 to deliver long-awaited innovation for patients with high unmet need blood-clotting disorders like Glanzmann thrombasthenia, Factor VII deficiency, Bernard Soulier syndrome, von Willebrand disease, and other serious disorders. | Directeur/Membre du Conseil | 01/01/2024 |
Atlas Venture Advisors, Inc.
![]() Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | - |
Anciens postes connus de Akshay Vaishnaw
Sociétés | Poste | Fin |
---|---|---|
EDITAS MEDICINE, INC. | Directeur/Membre du Conseil | 30/06/2024 |
VISTERRA INC | Directeur/Membre du Conseil | 01/07/2018 |
BIOGEN INC. | Corporate Officer/Principal | 01/01/2005 |
Formation de Akshay Vaishnaw
University of London | Doctorate Degree |
University of Cardiff | Undergraduate Degree |
Cardiff University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 4 |
---|---|
BIOGEN INC. | Health Technology |
ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
EDITAS MEDICINE, INC. | Health Technology |
SCHOLAR ROCK HOLDING CORPORATION | Health Technology |
Entreprise privées | 4 |
---|---|
Visterra, Inc.
![]() Visterra, Inc. Pharmaceuticals: MajorHealth Technology Visterra, Inc. Is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antibody-based therapies for kidney diseases, and other chronic diseases. It focuses on its research technology platform, HIEROTOPE technology. The company was founded by Alan L. Crane, Kevin J. Bitterman and Ram Sasisekharan on December 20, 2007 and is headquartered in Waltham, MA. | Health Technology |
Atlas Venture Advisors, Inc.
![]() Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Scholar Rock, Inc.
![]() Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Health Technology |
Hemab Therapeutics ApS
![]() Hemab Therapeutics ApS BiotechnologyHealth Technology Hemab Therapeutics ApS is a clinical-stage biotech company based in Copenhagen, Denmark and MA. The Danish company is focused on developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Hemab is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics to transform the treatment paradigm for patients with high unmet need. The company's strategic guidance, Hemab 1-2-5tm, targets the development of 5 independent assets by 2025 to deliver long-awaited innovation for patients with high unmet need blood-clotting disorders like Glanzmann thrombasthenia, Factor VII deficiency, Bernard Soulier syndrome, von Willebrand disease, and other serious disorders. | Health Technology |